Albert E. Heacox, Ph.D. Assumes Senior Vice President of Research and Development Position for CryoLife, Inc.
December 14 2004 - 8:30AM
PR Newswire (US)
Albert E. Heacox, Ph.D. Assumes Senior Vice President of Research
and Development Position for CryoLife, Inc. ATLANTA, Dec. 14
/PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE:CRY) a biomaterials
and biosurgical device company, announced today that Albert E.
Heacox, Ph.D. has assumed the position of Senior Vice President of
Research and Development of CryoLife, Inc. Reporting to Dr. Heacox
will be CryoLife's Research and Development Laboratory, Product and
Process Engineering and Aurazyme Pharmaceuticals' Research
Department. Dr. Heacox, (54) joined CryoLife in 1985 as Director of
Laboratory Operations. In 1989 he was promoted to Vice President of
Laboratory Operations and then in 2000 he was promoted to Senior
Vice President of Laboratory Operations for the Company. In his new
position he will continue to report to Steven G. Anderson,
President and CEO of CryoLife. Albert E. Heacox completed his B.S.
and M.S. degrees in biology at Adelphi University in New York in
1971 and 1974 respectively. In 1980 he received his Ph.D. in
zoology from Washington State University. In 1981 he completed his
post-doctorate training in cell biology from The University of
Cologne in Germany. Prior to joining CryoLife in 1985, he was a
research scientist for the U.S. Department of Agriculture in Fargo,
North Dakota. He replaces Kirby S. Black, Ph.D. who resigned to
pursue other interests. "CryoLife has an extensive portfolio of new
products in the Company's research pipeline and Al Heacox is the
perfect person to bring these new technologies and products to
fruition," said Steven G. Anderson, President and CEO. "In
addition, Dr. Heacox has over twenty years experience in preserving
mammalian cells and tissues and will shepherd the Company's many
new tissue preservation and materials technologies going forward."
Anderson added, "We wish Dr. Black the best in his new endeavors
and thank him for his many contributions to CryoLife." About
CryoLife, Inc. Founded in 1984, CryoLife, Inc. is a leader in the
processing and distribution of implantable living human tissues for
use in cardiovascular and vascular surgeries throughout the United
States and Canada. The Company's BioGlue Surgical Adhesive is FDA
approved as an adjunct to sutures and staples for use in adult
patients in open surgical repair of large vessels and is CE marked
in the European Community and approved in Canada for use in soft
tissue repair and approved in Australia for use in vascular and
pulmonary sealing and repair. The Company also manufactures the SG
Model #100 vascular graft, which is CE marked for distribution
within the European Community. For additional information about the
company, visit CryoLife's web site: http://www.cryolife.com/
Contact: Joseph T. Schepers Vice President, Corporate
Communications (770) 419-3355 DATASOURCE: CryoLife, Inc. CONTACT:
Joseph T. Schepers, Vice President, Corporate Communications of
CryoLife, Inc., +1-770-419-3355 Web site: http://www.cryolife.com/
Copyright
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jun 2024 to Jul 2024
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jul 2023 to Jul 2024